NGNE
NeurogeneBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary company disclosures show meaningful execution: Breakthrough Therapy designation, full enrollment in Embolden, more than half of participants dosed, and a planned mid-2026 data update keep NGN-401 on a credible late-stage path [#IR-2026-02-26][#IR-2026-03-24].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.8.
What can break
Cash burn or manufacturing delays could pull financing needs forward despite runway guidance into Q1 2028
Momentum
89
Value
41
Sentiment
40
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $24.00 · Bull $42.00 · Bear $9.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $81.00
Why
Momentum89 · Δ7d -1.8
Value41 · Δ7d +0.1
Sentiment40 · Δ7d +3.6
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
89
34% active weight
Current posture
7d trendFlat
Δ7d
-1.8
Δ21d
-6.8
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
40
33% active weight
Current posture
7d trendImproving
Δ7d
+3.6
Δ21d
+16.4
Why this grade
Composite grade B. Momentum 89.3 / Value 41.1 / Sentiment 40.5
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$435.18M
Beta
1.61
Shares Out
15.49M
P/E (TTM) · Derived
-6.6
P/S (TTM)
-
P/FCF (TTM) · Derived
-7.41
Rev YoY
-100.0%
EPS YoY
+17.0%
Gross Margin
-
Op Margin
-9702.2%
Net Debt
-$312.33M
Current Ratio
18.39
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology